In a May 7, 2024 press release, Seragon Biosciences announced that its aging intervention drug candidate, SRN-901, achieved one of the largest extensions of
Caloric restriction mimetics offer the benefits of calorie reduction without extreme diets, targeting pathways linked to aging for a longer, healthier life.
Rapamycin shows potential in extending lifespan, improving healthspan, and enhancing oral health, making it a key player in anti-aging research and human longevity.
Mitchell Lee, CEO of Ora Biomedical, is revolutionizing longevity research with high-throughput screening in C. elegans, aiming to screen over 1 million compounds in